Skip to main content
main-content

Medicine Matters branded image Welcome

We provide news, expert interviews, and educational resources to help you keep up with the latest developments in diabetes

Corticosteroid treatment and the consequences for glucose control

John Wilding

John Wilding highlights the issue of hyperglycemia triggered by use of high-dose steroids and discusses management strategies.

Residual cardiorenal risk high after SGLT2 inhibitor initiation in diabetic CKD

Heart pills

People with type 2 diabetes and chronic kidney disease have a high residual risk for cardiorenal events and high rates of treatment failure after initiation of SGLT2 inhibitors, real-world study findings indicate.

New additions to the Adis Journal Club – January update

Drugs Journal

Browse January's selection of peer-reviewed articles from the Adis journal portfolio. Curated by the editors and updated monthly. These papers highlight topical research and reviews for the benefit of Medicine Matters readers.

New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

IN FOCUS | Obesity & lifestyle interventions

01-11-2022 | Semaglutide | News

STEP 8: Semaglutide better than liraglutide at weight-management doses

Semaglutide 2.4 mg produces substantially more weight loss than liraglutide 3.0 mg in people with overweight or obesity but without diabetes, say the STEP 8 investigators.

Semaglutide for weight loss: The STEP and SELECT trials

Get the latest results and insights from the researchers.

IN FOCUS | Hypoglycemia

12-16-2021 | Hypoglycemia | Video

What is hypoglycemia-associated autonomic failure?

Sambit Das gives the highlights of his ESICON presentation on the etiology and management of hypoglycemia-associated autonomic failure.

VIEW FROM THE CLINIC | Hypoglycemia

Hypoglycemia presentations that require deviation from standard management are rare, but challenging. To learn how to proceed in such cases, read this series by Sanjay Kalra, outlining these instances and offering pragmatic advice.

Read now

IN FOCUS | Cardiovascular disorders

01-13-2022 | SGLT2 inhibitors | News

Residual cardiorenal risk high after SGLT2 inhibitor initiation in diabetic CKD

People with type 2 diabetes and chronic kidney disease have a high residual risk for cardiorenal events and high rates of treatment failure after initiation of SGLT2 inhibitors, real-world study findings indicate.

IN FOCUS | Tirzepatide

10-22-2021 | Tirzepatide | Video

SURPASS-4: Tirzepatide as an alternative to insulin glargine in type 2 diabetes

Stefano Del Prato discusses the advantages of tirzepatide over insulin glargine for people with type 2 diabetes, and how the SURPASS-4 findings fit with those of the rest of the clinical trial program (7:42).

The SURPASS trials

Get the latest reporting, researcher interviews, and independent commentary on tirzepatide for type 2 diabetes.

FEATURED WEB RESOURCE | Cushing’s Hub

Springer Healthcare is excited to present Cushing’s Hub, a unique online resource that collates and expertly curates the latest, clinically relevant information on Cushing’s syndrome. Cushing’s Hub identifies the best, most recently published literature about Cushing’s syndrome, presenting it in easy-to-digest formats, including editorials, news highlights, interactive case studies, animated abstracts, and succinct publication highlights. Overseen by an esteemed, independent Editorial BoardCushing’s Hub is brought to you by Springer Healthcare and is funded for educational purposes by HRA Pharma Rare Diseases.

Visit CushingsHub.com (opens in new window)

IN FOCUS | Kidney disease

01-13-2022 | SGLT2 inhibitors | News

Residual cardiorenal risk high after SGLT2 inhibitor initiation in diabetic CKD

People with type 2 diabetes and chronic kidney disease have a high residual risk for cardiorenal events and high rates of treatment failure after initiation of SGLT2 inhibitors, real-world study findings indicate.

IN FOCUS | SGLT2 inhibitors

01-13-2022 | SGLT2 inhibitors | News

Residual cardiorenal risk high after SGLT2 inhibitor initiation in diabetic CKD

People with type 2 diabetes and chronic kidney disease have a high residual risk for cardiorenal events and high rates of treatment failure after initiation of SGLT2 inhibitors, real-world study findings indicate.

IN FOCUS | GLP-1 receptor agonists

01-11-2022 | Semaglutide | News

STEP 8: Semaglutide better than liraglutide at weight-management doses

Semaglutide 2.4 mg produces substantially more weight loss than liraglutide 3.0 mg in people with overweight or obesity but without diabetes, say the STEP 8 investigators.

Stay informed with Medicine Matters

Get the latest developments in diabetes delivered straight to your inbox

Addressing suicide risk in diabetes

Learn about rates and risk, underlying psychological factors, and practical actions to support patients.

IN FOCUS | Mental health & psychosocial care

07-21-2021 | Disordered eating | News

Eating disorders tied to increased DKA, mortality risk in young people with type 1 diabetes

The presence of an eating disorder diagnosis significantly increases the risk for diabetic ketoacidosis and all-cause mortality in adolescents and young adults with type 1 diabetes, shows a population-based study.

IN FOCUS | Diabetes devices & technology

06-02-2021 | ATTD 2021 | Conference coverage | News

Studies support wider CGM access in type 2 diabetes

The results of two studies published in JAMA indicate that real-time continuous glucose monitoring benefits people with type 1 or type 2 diabetes on a range of insulin regimens and from a wide variety of backgrounds.

Flash glucose monitoring technology

Browse new slide sets summarizing the latest results from real-world studies.

Podcasts

Interviews with experts on diabetes patient care

Image Credits